In a 12-year-old child with cerebral palsy on levetiracetam (Keppra), being treated with intravenous ceftriaxone for a Proteus mirabilis febrile urinary tract infection, who is clinically improving but shows a rising C‑reactive protein after 5 days while the complete blood count remains normal, how should management be adjusted?

Continue Current Antibiotic Therapy and Monitor Clinically

In this clinically improving 12-year-old with cerebral palsy being treated for Proteus mirabilis UTI, you should continue IV ceftriaxone without modification despite the rising CRP, as clinical improvement takes precedence over isolated laboratory markers.

Clinical Reasoning

The patient demonstrates clear clinical improvement:

• Afebrile after initial fever
• Good oral intake
• Hemodynamically stable
• Normal CBC

The rising CRP from 2.8 to 7.2 mg/dL after 5 days of appropriate antibiotic therapy is not clinically significant in this context. CRP is an acute phase reactant that can lag behind clinical improvement by several days and does not necessarily indicate treatment failure when other parameters are improving 1.

Management Algorithm

1. Continue Current Therapy

• Maintain IV ceftriaxone at 50-100 mg/kg/day (appropriate for Proteus mirabilis UTI per sensitivity testing) 2
• Complete a 7-10 day course for febrile UTI/pyelonephritis 1
• The organism is sensitive to ceftriaxone, making this the optimal choice

2. Clinical Monitoring Parameters (Not Laboratory-Driven)

Focus on these clinical indicators rather than CRP:

• Temperature trends - Most critical marker; patient is already afebrile
• Oral intake and hydration status - Currently adequate
• Urinary symptoms - Though difficult to assess in CP patients
• General activity level and behavior
• Vital signs stability - Currently stable

3. When to Reassess Treatment

Only consider changing antibiotics if:

• Fever recurs after 48-72 hours of appropriate therapy 1
• Clinical deterioration (decreased intake, lethargy, hemodynamic instability)
• New symptoms emerge suggesting complications

Do NOT change therapy based solely on:

• Rising CRP in isolation
• Laboratory values when clinically improving

Special Considerations for Cerebral Palsy Patients

Children with CP have increased UTI risk due to:

• Neurogenic bladder dysfunction
• Impaired bladder emptying
• Chronic constipation
• Reduced mobility 3, 4

However, these factors do not change acute management when the patient is responding clinically.

Duration and Transition Planning

Complete 7-10 days total antibiotic therapy for this febrile UTI 1:

• Can transition to oral therapy after 48-72 hours if clinically stable and tolerating oral intake 1
• Oral options (if transitioning): amoxicillin-clavulanate or oral cephalosporin based on sensitivities
• No routine "proof of cure" urine culture needed if clinical improvement continues 1

Common Pitfalls to Avoid

1. Do not chase laboratory values when the patient is clinically improving - CRP elevation alone is not treatment failure
2. Do not broaden antibiotics unnecessarily - the organism is sensitive and patient is responding
3. Do not obtain repeat imaging (ultrasound already normal) unless clinical deterioration occurs
4. Do not stop antibiotics prematurely - complete the full 7-10 day course despite clinical improvement

Keppra Considerations

The patient's levetiracetam (Keppra) therapy is not relevant to this UTI management 5. Levetiracetam has minimal drug interactions and does not affect antibiotic metabolism or UTI treatment 5.

The key principle: Clinical improvement trumps isolated laboratory abnormalities. Continue effective therapy and monitor the patient, not just the numbers.